Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations

Journal of Biological Chemistry

Volumn 288, Issue 15, 2013, Pages 10472-10482

  Yu, Zhi Hong ^a   Xu, Jie ^a   Walls, Chad D ^a   Chen, Lan ^a   Zhang, Sheng ^a   Zhang, Ruoyu ^a   Wu, Li ^a   Wang, Lina ^a   Liu, Sijiu ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY;

BIOLOGY;

MUTANT PROTEIN; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCAFFOLD PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE MUTATION; GENE STRUCTURE; GENE SWITCHING; GENETIC ASSOCIATION; GROWTH STIMULATION; HUMAN; HUMAN CELL; LEOPARD SYNDROME; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; SHP2 GENE;

CRYSTALLOGRAPHY, X-RAY; HUMANS; LEOPARD SYNDROME; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876273572     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.450023     Document Type: Article

References (47)

1. Neel, B. G., Gu, H., and Pao, L. (2003) The "Shp"ing news. SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293
2. Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A., and Dallapiccola, B. (2002) Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet. 71, 389-394
3. Tartaglia, M., and Gelb, B. D. (2005) Noonan syndrome and related disorders. Genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 6, 45-68
4. Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J. D., and Gelb, B. D. (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia. Nat. Genet. 34, 148-150
5. Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., Richards, W. G., Du, J., Girard, L., Minna, J. D., Loh, M. L., Fisher, D. E., Velculescu, V. E., Vogelstein, B., Meyerson, M., Sellers, W. R., and Neel, B. G. (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64, 8816-8820
6. Sugimoto, S., Wandless, T.J., Shoelson, S.E., Neel, B.G., and Walsh, C.T. (1994) Activation of the SH2-containing protein tyrosine phosphatase, SH-PTPs by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J. Biol. Chem. 269, 13614-13622
7. Pluskey, S., Wandless, T.J., Walsh, C.T., and Shoelson, S.E. (1995) Potent stimulation of SHPTPs phosphatase activity by simultaneous occupancy of both SH2 domains. J. Biol. Chem. 270, 2897-2900
8. Pei, D., Wang, J., and Walsh, C.T. (1996) Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SHPTP1. Proc. Natl. Acad. Sci. U.S.A. 93, 1141-1145
9. Lechleider, R.J., Sugimoto, S., Bennett, A.M., Kashishian, A.S., Cooper, J.A., Shoelson, S.E., Walsh, C.T., and Neel, B.G. (1993) Activation of the SH2-containing phosphotyrosine phosphatase SH-PTPs by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. J. Biol. Chem. 268, 21478-21481
10. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., and Shoelson, S. E. (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450
11. Fragale, A., Tartaglia, M., Wu, J., and Gelb, B. D. (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23, 267-277
12. Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., and Neel, B. G. (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280, 30984-30993
13. Oishi, K., Gaengel, K., Krishnamoorthy, S., Kamiya, K., Kim, I. K., Ying, H., Weber, U., Perkins, L. A., Tartaglia, M., Mlodzik, M., Pick, L., and Gelb, B. D. (2006) Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. Hum. Mol. Genet. 15, 543-553
14. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., Burgt, I. v., Palleschi, A., Petrucci, T. C., Sorcini, M., Schoch, C., Foa, R., Emanuel, P. D., and Gelb, B. D. (2006) Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279-290
15. Martinelli, S., Torreri, P., Tinti, M., Stella, L., Bocchinfuso, G., Flex, E., Grottesi, A., Ceccarini, M., Palleschi, A., Cesareni, G., Castagnoli, L., Petrucci, T. C., Gelb, B. D., and Tartaglia, M. (2008) Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V, and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet. 17, 2018-2029
16. Hanna, N., Montagner, A., Lee, W. H., Miteva, M., Vidal, M., Vidaud, M., Parfait, B., and Raynal, P. (2006) Reduced phosphatase activity of SHP-2 in LEOPARD syndrome. Consequences for P13K binding on Gab1. FEBS Lett. 580, 2477-2482
17. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., and Neel, B. G. (2006) PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281, 6785-6792
18. Otwinowski, Z., and Minor, W. (1997) in Macromolecular Crystallography, Part A, pp 307-326, Academic Press Inc., San Diego, CA
19. Vagin, A., and Teplyakov, A. (1997) MOLREP. an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022-1025
20. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., Mc-Coy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX. a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221
21. Case, D. A., Cheatham, T. E., 3rd, Darden, T., Gohlke, H., Luo, R., Merz, K. M., Jr., Onufriev, A., Simmerling, C., Wang, B., and Woods, R. J. (2005) The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688
22. Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., and Cheatham, T. E., 3rd (2000) Calculating structures and free energies of complex molecules. Combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897
23. Weis, D. D., Engen, J. R., and Kass, I. J. (2006) Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom. 17, 1700-1703
24. Jia, Z., Barford, D., Flint, A. J., and Tonks, N. K. (1995) Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 268, 1754-1758
25. Sarmiento, M., Zhao, Y., Gordon, S. J., and Zhang, Z. Y. (1998) Molecular basis for substrate specificity of protein-tyrosine phosphatase 1B. J. Biol. Chem. 273, 26368-26374
26. Hoofnagle, A. N., Resing, K. A., and Ahn, N. G. (2003) Protein analysis by hydrogen exchange mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 32, 1-25
27. Chen, B., Bronson, R. T., Klaman, L. D., Hampton, T. G., Wang, J. F., Green, P. J., Magnuson, T., Douglas, P. S., Morgan, J. P., and Neel, B. G. (2000) Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24, 296-299
28. Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L., and Wu, J. (2000) Requirement of SHP2 binding to Grb2-associated binder-1 for mitogenactivated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor. J. Biol. Chem. 275, 13842-13848
29. Cunnick, J. M., Mei, L., Doupnik, C. A., and Wu, J. (2001) Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J. Biol. Chem. 276, 24380-24387
30. Deb, T. B., Wong, L., Salomon, D. S., Zhou, G., Dixon, J. E., Gutkind, J. S., Thompson, S. A., and Johnson, G. R. (1998) A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in MAP, but not c-jun amino-terminal kinase activation. J. Biol. Chem. 273, 16643-16646
31. Qu, C. K., Yu, W. M., Azzarelli, B., and Feng, G. S. (1999) Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc. Natl. Acad. Sci. U.S.A. 96, 8528-8533
32. Ren, Y., Meng, S., Mei, L., Zhao, Z. J., Jove, R., and Wu, J. (2004) Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J. Biol. Chem. 279, 8497-8505
33. Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., and Neel, B. G. (2004) Mouse model of Noonan syndrome reveals cell type-and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10, 849-857
34. Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., Akashi, K., Gilliland, D. G., and Neel, B. G. (2005) Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7, 179-191
35. Krenz, M., Gulick, J., Osinska, H. E., Colbert, M. C., Molkentin, J. D., and Robbins, J. (2008) Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc. Natl. Acad. Sci. U.S.A. 105, 18930-18935
36. Carta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sarkozy, A., Digilio, C., Palleschi, A., Pizzuti, A., Grammatico, P., Zampino, G., Dallapiccola, B., Gelb, B. D., and Tartaglia, M. (2006) Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype. Am. J. Hum. Genet. 79, 129-135
37. Schubbert, S., Zenker, M., Rowe, S. L., Boll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L. E., Nguyen, H., West, B., Zhang, K. Y., Sistermans, E., Rauch, A., Niemeyer, C. M., Shannon, K., and Kratz, C. P. (2006) Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38, 331-336
38. Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., and Kucherlapati, R. S. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet. 39, 70-74
39. Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., Ustaszewska, A., Martin, J., Bristow, J., Carta, C., Lepri, F., Neri, C., Vasta, I., Gibson, K., Curry, C. J., Siguero, J. P., Digilio, M. C., Zampino, G., Dallapiccola, B., Bar-Sagi, D., and Gelb, B. D. (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet. 39, 75-79
40. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., and Matsubara, Y. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 37, 1038-1040
41. Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C., Gillessen-Kaesbach, G., Wieczorek, D., Kavamura, M. I., Kurosawa, K., Ohashi, H., Wilson, L., Heron, D., Bonneau, D., Corona, G., Kaname, T., Naritomi, K., Baumann, C., Matsumoto, N., Kato, K., Kure, S., and Matsubara, Y. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38, 294-296
42. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., and Rauen, K. A. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290
43. Gelb, B. D., and Tartaglia, M. (2006) Noonan syndrome and related disorders. Dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 15, R220-R226
44. Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M., and Fryns, J. P. (2002) PTPN11 mutations in LEOPARD syndrome. J. Med. Genet. 39, 571-574
45. Oishi, K., Zhang, H., Gault, W. J., Wang, C. J., Tan, C. C., Kim, I. K., Ying, H., Rahman, T., Pica, N., Tartaglia, M., Mlodzik, M., and Gelb, B. D. (2009) Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum. Mol. Genet. 18, 193-201
46. Carvajal-Vergara, X., Sevilla, A., D'Souza, S. L., Ang, Y. S., Schaniel, C., Lee, D. F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., Ge, Y., Cohen, N., Edelmann, L. J., Chang, B., Waghray, A., Su, J., Pardo, S., Lichtenbelt, K. D., Tartaglia, M., Gelb, B. D., and Lemischka, I. R. (2010) Patient-specific induced pluripotent stem cell-derived models of LEOPARD syndrome. Nature 465, 808-812
47. Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., Pogna, E. A., Schackwitz, W., Ustaszewska, A., Landstrom, A., Bos, J. M., Ommen, S. R., Esposito, G., Lepri, F., Faul, C., Mundel, P., Lopez Siguero, J. P., Tenconi, R., Selicorni, A., Rossi, C., Mazzanti, L., Torrente, I., Marino, B., Digilio, M. C., Zampino, G., Ackerman, M. J., Dallapiccola, B., Tartaglia, M., and Gelb, B. D. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 39, 1007-1012